Lung Transplantation in Patients with Previous or Unknown Oncological Disease: Evaluation of Short- and Long-Term Outcomes
The accurate selection of the recipient is a crucial aspect in the field of lung transplantation (LTX), especially if patients were previously affected by oncological disease. The aim of this bicentric retrospective study was to evaluate short- and long-term outcomes in patients with previous oncolo...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-01-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/16/3/538 |
| _version_ | 1797319017802760192 |
|---|---|
| author | Chiara Catelli Eleonora Faccioli Stefano Silvestrin Giulia Lorenzoni Luca Luzzi David Bennett Marco Schiavon Alessio Campisi Elena Bargagli Andrea Dell’Amore Federico Rea |
| author_facet | Chiara Catelli Eleonora Faccioli Stefano Silvestrin Giulia Lorenzoni Luca Luzzi David Bennett Marco Schiavon Alessio Campisi Elena Bargagli Andrea Dell’Amore Federico Rea |
| author_sort | Chiara Catelli |
| collection | DOAJ |
| description | The accurate selection of the recipient is a crucial aspect in the field of lung transplantation (LTX), especially if patients were previously affected by oncological disease. The aim of this bicentric retrospective study was to evaluate short- and long-term outcomes in patients with previous oncological disease or unknown neoplasia found on native lungs submitted to LTX, compared to a control group. A total of 433 patients were included in the analysis, 31 with malignancies (Group 1) and 402 without neoplastic disease (Group 2). The two groups were compared in terms of short- and long-term outcomes. Patients in Group 1 were older (median age 58 years vs. 50 years, <i>p</i> = 0.039) and mostly affected by idiopathic pulmonary fibrosis (55% vs. 40% <i>p</i> = 0.002). Even though in Group 1 a lower rate of late post-operative complications was found (23% vs. 45%, <i>p</i> = 0.018), the median overall survival (OS) was lower compared to the control group (10 months vs. 29 months, <i>p</i> = 0.015). LTX represents a viable therapeutic option for patients with end-stage lung disease and a history of neoplastic disease. However, every case should be carefully debated in a multidisciplinary setting, considering oncological (histology, stage, and proper disease free-interval) and clinical factors (patient’s age and comorbidities). A scrupulous post-transplant follow-up is especially mandatory in those cases. |
| first_indexed | 2024-03-08T03:59:48Z |
| format | Article |
| id | doaj.art-9db22fdca01a489887547b24b21bffc3 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-08T03:59:48Z |
| publishDate | 2024-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-9db22fdca01a489887547b24b21bffc32024-02-09T15:08:56ZengMDPI AGCancers2072-66942024-01-0116353810.3390/cancers16030538Lung Transplantation in Patients with Previous or Unknown Oncological Disease: Evaluation of Short- and Long-Term OutcomesChiara Catelli0Eleonora Faccioli1Stefano Silvestrin2Giulia Lorenzoni3Luca Luzzi4David Bennett5Marco Schiavon6Alessio Campisi7Elena Bargagli8Andrea Dell’Amore9Federico Rea10Thoracic Surgery Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, 35121 Padova, ItalyThoracic Surgery Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, 35121 Padova, ItalyThoracic Surgery Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, 35121 Padova, ItalyUnit of Biostatistics Epidemiology and Public Health, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, 35121 Padova, ItalyLung Transplant Unit, University of Siena, Azienda Ospedaliero-Universitaria Senese, 53100 Siena, ItalyRespiratory Disease and Lung Transplant Unit, University of Siena, Azienda Ospedaliero-Universitaria Senese, 53100 Siena, ItalyThoracic Surgery Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, 35121 Padova, ItalyDepartment of Thoracic Surgery, University and Hospital Trust-Borgo Trento, 37126 Verona, ItalyRespiratory Disease and Lung Transplant Unit, University of Siena, Azienda Ospedaliero-Universitaria Senese, 53100 Siena, ItalyThoracic Surgery Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, 35121 Padova, ItalyThoracic Surgery Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, 35121 Padova, ItalyThe accurate selection of the recipient is a crucial aspect in the field of lung transplantation (LTX), especially if patients were previously affected by oncological disease. The aim of this bicentric retrospective study was to evaluate short- and long-term outcomes in patients with previous oncological disease or unknown neoplasia found on native lungs submitted to LTX, compared to a control group. A total of 433 patients were included in the analysis, 31 with malignancies (Group 1) and 402 without neoplastic disease (Group 2). The two groups were compared in terms of short- and long-term outcomes. Patients in Group 1 were older (median age 58 years vs. 50 years, <i>p</i> = 0.039) and mostly affected by idiopathic pulmonary fibrosis (55% vs. 40% <i>p</i> = 0.002). Even though in Group 1 a lower rate of late post-operative complications was found (23% vs. 45%, <i>p</i> = 0.018), the median overall survival (OS) was lower compared to the control group (10 months vs. 29 months, <i>p</i> = 0.015). LTX represents a viable therapeutic option for patients with end-stage lung disease and a history of neoplastic disease. However, every case should be carefully debated in a multidisciplinary setting, considering oncological (histology, stage, and proper disease free-interval) and clinical factors (patient’s age and comorbidities). A scrupulous post-transplant follow-up is especially mandatory in those cases.https://www.mdpi.com/2072-6694/16/3/538cancerlung transplantationsurvivaloutcomes |
| spellingShingle | Chiara Catelli Eleonora Faccioli Stefano Silvestrin Giulia Lorenzoni Luca Luzzi David Bennett Marco Schiavon Alessio Campisi Elena Bargagli Andrea Dell’Amore Federico Rea Lung Transplantation in Patients with Previous or Unknown Oncological Disease: Evaluation of Short- and Long-Term Outcomes Cancers cancer lung transplantation survival outcomes |
| title | Lung Transplantation in Patients with Previous or Unknown Oncological Disease: Evaluation of Short- and Long-Term Outcomes |
| title_full | Lung Transplantation in Patients with Previous or Unknown Oncological Disease: Evaluation of Short- and Long-Term Outcomes |
| title_fullStr | Lung Transplantation in Patients with Previous or Unknown Oncological Disease: Evaluation of Short- and Long-Term Outcomes |
| title_full_unstemmed | Lung Transplantation in Patients with Previous or Unknown Oncological Disease: Evaluation of Short- and Long-Term Outcomes |
| title_short | Lung Transplantation in Patients with Previous or Unknown Oncological Disease: Evaluation of Short- and Long-Term Outcomes |
| title_sort | lung transplantation in patients with previous or unknown oncological disease evaluation of short and long term outcomes |
| topic | cancer lung transplantation survival outcomes |
| url | https://www.mdpi.com/2072-6694/16/3/538 |
| work_keys_str_mv | AT chiaracatelli lungtransplantationinpatientswithpreviousorunknownoncologicaldiseaseevaluationofshortandlongtermoutcomes AT eleonorafaccioli lungtransplantationinpatientswithpreviousorunknownoncologicaldiseaseevaluationofshortandlongtermoutcomes AT stefanosilvestrin lungtransplantationinpatientswithpreviousorunknownoncologicaldiseaseevaluationofshortandlongtermoutcomes AT giulialorenzoni lungtransplantationinpatientswithpreviousorunknownoncologicaldiseaseevaluationofshortandlongtermoutcomes AT lucaluzzi lungtransplantationinpatientswithpreviousorunknownoncologicaldiseaseevaluationofshortandlongtermoutcomes AT davidbennett lungtransplantationinpatientswithpreviousorunknownoncologicaldiseaseevaluationofshortandlongtermoutcomes AT marcoschiavon lungtransplantationinpatientswithpreviousorunknownoncologicaldiseaseevaluationofshortandlongtermoutcomes AT alessiocampisi lungtransplantationinpatientswithpreviousorunknownoncologicaldiseaseevaluationofshortandlongtermoutcomes AT elenabargagli lungtransplantationinpatientswithpreviousorunknownoncologicaldiseaseevaluationofshortandlongtermoutcomes AT andreadellamore lungtransplantationinpatientswithpreviousorunknownoncologicaldiseaseevaluationofshortandlongtermoutcomes AT federicorea lungtransplantationinpatientswithpreviousorunknownoncologicaldiseaseevaluationofshortandlongtermoutcomes |